Psoriatic Immune Response to Tildrakizumab
ConditionPsoriasis Vulgaris
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorUniversity of California, San Francisco
About this trial
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Eligibility criteria
Qualifiers
18 years of age or older
Patients with moderate-severe psoriasis or > 5% body surface area affected.
Disqualifiers
taking systemic immunosuppressives in the last 4 weeks
pregnancy
severe immunodeficiency (either from genetic or infectious causes).
tuberculosis or other active serious infection
Trial design
Treatments tested in this trial
- Tildrakizumab Prefilled Syringe
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
University of California, San Francisco
Lead sponsor
Sun Pharmaceutical Industries Limited
Collaborator
Source ClinicalTrials.gov